Parent–child relationships and adolescents’ life satisfaction across the first decade of the new millennium

This is the peer reviewed version of the following article: Antonia Jiménez-Iglesias, Irene GarcÍa-Moya, and Carmen Moreno, ‘Parent–Child Relationships and Adolescents' Life Satisfaction Across the First Decade of the New Millennium’, Family Relations, Vol. 66 (3): 512-526, July 2017, which has been published in final form at: https://doi.org/10.1111/fare.12249. Under embargo until 31 July 2018. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.Objective: To examine whether changes occurred in parent–child relationships (maternal and paternal affection, ease of communication with the mother and father, maternal and paternal knowledge, and family activities) between 2002 and 2010 in boys and girls and to examine the contributions of these family dimensions to life satisfaction. Background: Although parent–child relationships may be affected by social change, there are few investigations of change in parent–child relationships over time. Method: The sample consisted of 46,593 adolescents between 11 to 18 years of age who participated in the 2002, 2006, or 2010 editions of the Health Behaviour in School-aged Children (HBSC) study in Spain. Trend analysis including univariate analyses of variance (ANOVAs) and factorial ANOVAs were conducted separately for boys and girls, and effect size tests were calculated. Results: Communication with fathers and family activities statistically increased across HBSC editions and parent–child relationships were positively associated with life satisfaction across the examined period. Conclusion: There were small positive changes in some family dimensions, and some of them were increasingly important for adolescent life satisfaction over time. Implications: Interventions for strengthening parent-child relationships and promoting adolescent well-being should include mothers and fathers and emphasize affection, communication, and family activities.Peer reviewedFinal Accepted Versio

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury

A proportion of patients infected with severe acute respiratory syndrome coronavirus 2 experience a range of neuropsychiatric symptoms months after infection, including cognitive deficits, depression and anxiety. The mechanisms underpinning such symptoms remain elusive. Recent research has demonstrated that nervous system injury can occur during COVID-19. Whether ongoing neural injury in the months after COVID-19 accounts for the ongoing or emergent neuropsychiatric symptoms is unclear. Within a large prospective cohort study of adult survivors who were hospitalized for severe acute respiratory syndrome coronavirus 2 infection, we analysed plasma markers of nervous system injury and astrocytic activation, measured 6 months post-infection: neurofilament light, glial fibrillary acidic protein and total tau protein. We assessed whether these markers were associated with the severity of the acute COVID-19 illness and with post-acute neuropsychiatric symptoms (as measured by the Patient Health Questionnaire for depression, the General Anxiety Disorder assessment for anxiety, the Montreal Cognitive Assessment for objective cognitive deficit and the cognitive items of the Patient Symptom Questionnaire for subjective cognitive deficit) at 6 months and 1 year post-hospital discharge from COVID-19. No robust associations were found between markers of nervous system injury and severity of acute COVID-19 (except for an association of small effect size between duration of admission and neurofilament light) nor with post-acute neuropsychiatric symptoms. These results suggest that ongoing neuropsychiatric symptoms are not due to ongoing neural injury

Long COVID and cardiovascular disease: a prospective cohort study

Background Pre-existing cardiovascular disease (CVD) or cardiovascular risk factors have been associated with an increased risk of complications following hospitalisation with COVID-19, but their impact on the rate of recovery following discharge is not known. Objectives To determine whether the rate of patient-perceived recovery following hospitalisation with COVID-19 was affected by the presence of CVD or cardiovascular risk factors. Methods In a multicentre prospective cohort study, patients were recruited following discharge from the hospital with COVID-19 undertaking two comprehensive assessments at 5 months and 12 months. Patients were stratified by the presence of either CVD or cardiovascular risk factors prior to hospitalisation with COVID-19 and compared with controls with neither. Full recovery was determined by the response to a patient-perceived evaluation of full recovery from COVID-19 in the context of physical, physiological and cognitive determinants of health. Results From a total population of 2545 patients (38.8% women), 472 (18.5%) and 1355 (53.2%) had CVD or cardiovascular risk factors, respectively. Compared with controls (n=718), patients with CVD and cardiovascular risk factors were older and more likely to have had severe COVID-19. Full recovery was significantly lower at 12 months in patients with CVD (adjusted OR (aOR) 0.62, 95% CI 0.43 to 0.89) and cardiovascular risk factors (aOR 0.66, 95% CI 0.50 to 0.86). Conclusion Patients with CVD or cardiovascular risk factors had a delayed recovery at 12 months following hospitalisation with COVID-19. Targeted interventions to reduce the impact of COVID-19 in patients with cardiovascular disease remain an unmet need

Engaged Service-Learning and the Experiential Learning Requirement at UGA: A Case Study

How do a large public research university, a college within that university, individual departments, and faculty members respond to a campus-wide mandate for experiential learning? Beginning in the Fall of 2016, all incoming undergraduate students at the University of Georgia (UGA) will be required to fulfill an experiential learning requirement prior to graduation. UGA defines experiential learning as “the development of knowledge, skills, abilities, values, behaviors, and attitudes via first-hand experiences outside of traditional classroom structures” within a domestic or global setting. With this initiative, UGA intends to become one of the largest public universities in the nation to provide each of its students with high impact, experiential learning opportunities intended to enhance academic performance and better prepare them for graduate school or careers. Although the university has hired a Director of Experiential Learning, reporting to the Office of the Vice President for Instruction, to bolster stewardship of the new experiential learning effort, the specific ways and courses for students to fulfill the requirement are being developed and approved by each of UGA’s schools and colleges serving undergraduates; academic service-learning courses will likely be the most frequent method by which this requirement will be met. For this presentation, we provide a case study of how Experiential Learning requirement is being conceptualized and implemented at several different levels: university-wide, then by one college--the College of Family and Consumer Sciences (FACS)—and the perspective of individual faculty members and departments nested within that setting. FACS operationalizes experiential learning through domestic or international study programs, internships, undergraduate research, service-learning, and directed study. Of these, service-learning is both the most frequent and most emphasized in FACS, building upon existing strengths. As a part of the plan to meet the experiential learning requirement, FACS has identified an initial 16 service-learning courses across 5 departments within the college. In this presentation, we overview the development and implementation of the university’s experiential learning requirement, campus-wide as well as within one particular college (FACS). The presentation shares specific examples of engaged service-learning from multiple courses across different departments, student learning outcomes, impact in the community, and the challenges experienced. Two faculty at FACS who are experienced with service-learning, and have taken part in the UGA Service-Learning Fellows faculty development program, describe the service-learning courses that they teach (in human development and disability, and in adolescent development) and how these courses align with this ‘learning by doing’ focus newly emphasized by UGA. In addition, anticipated benefits to the community and to student learning as well as the expected challenges to implementing service-learning courses to meet the new experiential learning requirement will be shared and discussed. Finally, the presentation will engage audience members in considering what lessons from such a university-wide initiative can be transferred to their own settings